Неинвазивные методы диагностики и лечения резус-сенсибилизации

1. Visser G.H.A., Di Renzo G.C., Spitalnik S.L. The continuing burden of Rh disease 50 years after the introduction of anti-Rh(D) immunoglobin prophylaxis: call to action. FIGO Committee Safe Motherhood and Newborn Health. Am J Obstet Gynecol. 2019 Sep;221(3):227.e1-227.e4. doi: 10.1016/j.ajog.2019.05.019. Epub 2019 May 20.
2. Houston B.L., Govia R., Abou-Setta A.M., et al. Severe Rh alloimmunization and hemolytic disease of the fetus managed with plasmapheresis, intravenous immunoglobulin and intrauterine transfusion: A case report. Transfusion and Apheresis Science. 2015; 53(3): 399-402. DOI: 10.1016/j.transci.2015.07.010
3. Zipursky A., Bhutani V.K., Odame I. Rhesus disease: a global prevention strategy. Lancet Child Adolesc Health. 2018; 2(7): 536-542. doi: 10.1016/S2352-4642(18)30071-3
4. Савельева Г.М., Конопляников А.Г., Курцер М.А. Резус-изоиммунизация. Старые проблемы. Новые решения. Вопросы гинекологии, акушерства, перинатологии. 2005; 4(3): 89-93.
5. Кулаков В.И. Новые технологии и научные приоритеты в акушерстве и гинекологии. Акушерство и гинекология. 2002; 5: 3–5.
6. Донсков С.И., Беляков В.В., Кравчук О.А. Динамика аллоиммунизации населения отдельных регионов Российской Федерации и Республики Беларусь в 2000-2017 гг.
7. Ghesquière L., Garabedian C., Coulon C., et al. Management of red blood cell alloimmunization in pregnancy. J Gynecol Obstet Hum Reprod. 2018; 47(5):197-204. http://dx.doi.org/10.1016/j.jogoh.2018.02.001
8. Суханова Л.П. Динамика перинатальной смертности в акушерских стационарах России в 1991-2002 гг. Акушерство и гинекология. 2005; 4:46-8.
9. Фролова О.Г., Токова З.З. Основные показатели деятельности акушерско-гинекологической службы и репродуктивного здоровья. Акушерство и гинекология. 2005; 1: 3-6.
10. Slootweg Y.M., Lindenburg I.T., Koelewijn J.M., Van Kamp I.L., Oepkes D., De Haas M. Predicting anti-Kell mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management. Am J Obstet Gynecol. 2018; 219(4): 393.e1-393.e8. doi: 10.1016/j.ajog.2018.07.020
11. Webb J., Delaney M. Blood Cell Alloimmunization in the Pregnant Patient. Transfus Med Rev. 2018; 32(4): 213-219. DOI: 10.1053/j.seminhematol.2005.04.007
12. Сухих Г.Т., Федорова Т.А., Митря И.В. Лечение резус-сенсибилизациис использованием лечебного плазмафереза и иммуноглобулинотерапии. Медицинская технология. 2011 г.
13. Finning K.M., Chitty L.S. Non-invasive fetal sex determination: Impact on clinical practice. Semin Fetal Neonatal Med. 2008; 13(2):69–75. doi: 10.1016/j.siny.2007.12.007
14. Dovc-Drnovsek T., Klemenc P., Toplak N., et al. Reliable Determination of Fetal RhD Status by RHD Genotyping from Maternal Plasma. Transfusion Medicine and Hemotherapy. 2013; 40(1): 37–43. doi: 10.1159/000345682.
15. Turley E., McGowan E.C., Hyland C.A., et al. Severe hemolytic disease of the fetus and newborn due to allo-anti-D in a patient with a partial DEL phenotype arising from the variant allele described as RHD*148+1T (RHD*01EL.31). Transfusion. 2018; 10: 2260–4. doi: 10.1111/trf.14944.
16. Papantoniou N., Daskalakis G., Anastasakis E., Marinopoulos S., Mesogitis S., Antsaklis A. Increasing the noninvasive management of rhesus isoimmunization. Int J Gynaecol Obstet. 2008;101(3): 281–4. doi: 10.1016/j.ijgo.2007.11.021
17. Dündar Yenilmez E., Kökbaş U., Kartlaşmış K., et al. A new biosensor for noninvasive determination of fetal RHD status in maternal blood of RhD negative pregnant women. PLoS One. 2018; 13(6): e0197855. doi: 10.1371/journal.pone.0197855
18. Illanes S., Soothill P. Noninvasive approach for the management of hemolytic disease of the fetus. Expert Rev Hematol. 2009; 2(5): 577-82. doi: 10.1586/ehm.09.45
19. Samson J., Block D., Mari G. Middle cerebral artery Doppler for managing fetal anemia. Clin Obstet Gynecol. 2010; 53(4): 851–57. doi: 10.1097/GRF.0b013e3181fbaf6d
20. Cabral A.C., Reis Z.S., Apocalypse I.G., et al. Combined use of the cardiofemoral index and middle cerebral artery Doppler velocimetry for the prediction of fetal anemia. Int J Gynecol Obstet. 2010; 111(3): 205-8. doi: 10.1016/j.ijgo.2010.07.017
21. Papantoniou N., Sifakis S., Antsaklis A.. J. Therapeutic management of fetal anemia: review of standard practice and alternative treatment options. Perinat. Med. 2013; 41(1): 71–82. DOI: 10.1515/jpm-2012-0093
22. Sueters M., Arabin B., Oepkes D. Doppler sonography for predicting fetal anemia caused by massive fetomaternal hemorrhage. Ultrasound Obstet Gynecol. 2003; 22(2):186-9. DOI: 10.1002/uog.190
23. Mari G. Noninvasive Diagnosis by Doppler Ultrasonography of fetal anemia due to maternal red-cell alloimmunization..  Obstetrical and Gynecological Survey. 2000; 55(6):341-342. DOI: 10.1097/00006254-200006000-00005
24. Poissonnier M.H., Picone O., Brossard Y., et al. Intravenous fetal exchange transfusion before 22 weeks of gestation in early and severe red-cell fetomaternal alloimmunization. Fetal Diagn Ther. 2003; 6: 467-71. DOI: 10.1159/000073145
25. Somerset D.A., Moore A., Whittle M.J., et al. An audit of outcome in intravascular transfusions using the intrahepatic portion of the fetal umbilical vein compared to cordocentesis.. Fetal Diagn Ther. 2006; 21(3): 272-6. http://dx.doi.org/10.1159/000091355
26. Weiner C.P., Estle L.Managment of fetal hemolytic disease by cordocentesis. Am J Obstet Gynecol. 1991; 165(3): 546-53. DOI: 10.1016/0002-9378(91)90281-u
27. Fernández Alba J.J., León R., González-Macías C., et al. Treatment of D alloimmunization in pregnancy with plasmapheresis and intravenous immune globulin: case report. Transfus Apher Sci. 2014; 51(1):70-2. doi: 10.1016/j.transci.2014.02.026
28. Palfi M. Selbingb A., Berlina G. A case of severe Rh (D) alloimmunization treated by intensive plasma exchange and high-dose intravenous immunoglobulin. Transfusion and Apheresis Science. 2006;35(2):131-136. DOI: 10.1016/j.transci.2006.07.002
29. Novak D.J., Tyler L.N., Reddy R.L., et al. Barsoom Plasmapheresis and Intravenous Immune Globulin for the Treatment of D Alloimmunization in Pregnancy. J Clin Apher. 2008;23(6):183-5. doi: 10.1002/jca.20180
30. Cambray-Gutiérrez J.C., García-Ramírez U.N., Del Rivero-Hernández L.G., et al. Use of intravenous immunoglobulin in pregnancy. Report of a patient with common variable immunodeficiency. Rev Alerg Mex. 2016; 63(3): 311-315. DOI: 10.29262/ram.v63i3.152
31. 31. Schwartz J., Padmanabhan A., Aqui N., et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016 Jun;31(3):149-62. doi: 10.1002/jca.21470
32. Zwiers C., van Kamp I., Oepkes D., et al. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn – review on current management and outcome. Expert Rev Hematol. 2017; 3: 337-44. doi: 10.1080/17474086.2017.1305265
33. Bellone M., Boctor F.N. Therapeutic plasma exchange and intravenous immunoglobulin as primary therapy for D alloimmunization in pregnancy precludes the need for intrauterine transfusion. Transfusion. 2014; 54(8):2118-21. DOI: 10.1111/trf.12633 ·
34. Scott J.R., Ward K. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization. Am J Obst Gyn. 1988; 159(5): 1055-56.
35. Ruma M.S., Lubarsky S.L. Combined plasmapheresis and intravenous immune globulin for the treatment of see maternal red cell alloimmunization. Am J Obstet Gynecol. 2007; 196(2):138.e1-6. DOI: 10.1016/j.ajog.2006.10.890
36. Colpo A., Tison T., Gervasi M.T., et al. Personalized treatment with immunoadsorption and intravenous immunoglobulin in a case of severe Rh alloimmunization during pregnancy unresponsive to plasma - exchange. Transfusion and Apheresis Science. 2017; 56(3): 480-3. DOI: 10.1016/j.transci.2017.05.024
37. Fernandez- Jimenez- Marco M.C., Hernandez D., Gonzalez A., et al. Treatment with plasmapheresis and intravenous immunoglobulin in pregnancies complicated with anti-PP1Pk or anti-K immunization: a report of two patients. Vox Sanguinis. 2001; 80: 117–20. DOI: 10.1046/j.1423-0410.2001.00021.x

Поступила 20.06.2019

Принята в печать 21.06.2019